Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs 2,637

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 30 of 55

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Vulvar squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

    phase 2 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3)

    phase 2 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    Squamous cell carcinoma of vulva/vagina, Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of penis, Squamous cell carcinoma of cervix, Squamous cell carcinoma of anus

    phase 2 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  8. KEYTRUDA for Locally recurrent, inoperable…

    Istituto Gentili S.r.l.

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  9. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  10. KL264-01

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  11. KN046

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  12. KN046

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  13. KTE-C19-102

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  15. Karelizumab combined with etoposide and cisplatin

    Jian Li

    Carcinoma

    phase 2 small molecule active

    1 trial

  16. L2023-K003-002

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  18. LB101-101

    Centessa Pharmaceuticals plc

    Advanced solid tumors

    phase 2 other active

    1 trial

  19. LB1410

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  20. LBH581

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  21. LBL-007

    BEONE MEDICINES AUS PTY LTD

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  22. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  23. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  24. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  25. LEN+SIN+DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 other active

    1 trial

  26. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  27. LETROZOLE, FULVESTRANT

    Pfizer Australia Pty Ltd

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  28. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Cutaneous squamous cell carcinoma (ccSCC)

    phase 2 small molecule active

    1 trial

  29. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    basal cell carcinoma

    phase 2 small molecule active

    1 trial

  30. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. LM-302

    LaNova Medicines Limited

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  32. LN-145

    Iovance Biotherapeutics B.V.

    Non Small Cell Lung Cancer

    phase 2 mab terminated

    1 trial

  33. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  34. LN-145

    Iovance Biotherapeutics B.V.

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial

  35. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  36. LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  37. LOLA trial

    Fondazione Telethon ETS

    gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)

    phase 2 small molecule active

    1 trial

  38. LOTS-GC-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  39. LOXO-BTK-18001 BRUIN

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  40. LOXO-RAS-20001

    Eli Lilly Co.

    KRAS G12C-Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  41. LOXO-RET-18036

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  42. LTS17704

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  43. LY2157299

    Eli Lilly and Company

    Carcinoma, Hepatocellular

    phase 2 small molecule completed

    1 trial

  44. LY2875358, ERLOTINIB

    Eli Lilly Co.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. Lacutamab

    Lacuna Pharma Pty Ltd

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    phase 2 small molecule active

    1 trial

  46. Lapatinib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  47. Lenalidomide

    United Therapeutics Europe Ltd

    Recurrent Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  48. Lenalidomide [Leavdo®]

    Hospital Authority, Hong Kong

    Antibiotics-unresponsive MALT Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,637 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.